婴儿白血病化疗疗效分析  

Analysis on therapeutic effect of infantile leukemia

作　　者：潘虹宇 吴南海 刘周阳 吴敏媛[3] 孙媛 鲍亮 员菡子 PAN Hongyu;WU Nanhai;LIU Zhouyang;WU Minyuan;SUN Yuan;BAO Liang;YUAN Hanzi(Department of Pediatrics,Sixth Medical Center of PLA General Hospital,Beijing 100048,China;Beijing Jingdu Children′s Hospital,Beijing 102208, China;Hematology Oncology Center,Beijing Children′s Hospital,Beijing 100045,China)

机构地区：[1]中国人民解放军总医院第六医学中心儿科,北京100048 [2]京都儿童医院,北京102208 [3]国家儿童医学中心北京儿童医院血液肿瘤中心,北京100045

出　　处：《中国小儿血液与肿瘤杂志》2019年第3期124-130,共7页Journal of China Pediatric Blood and Cancer

摘　　要：目的回顾性分析CCLG-ALL 2008和BCH-AML 05方案治疗婴儿白血病疗效,为改进婴儿白血病的治疗提供临床资料。方法 2011年1月-2019年1月期间符合入组标准的32例婴儿白血病患儿,其中20例婴儿ALL患儿接受了CCLG-ALL 2008方案治疗,合并MLL基因重排(MLL-r)者12例,无MLL-r者8例;12例婴儿AML接受BCH-AML 05方案治疗。回顾性分析病人治疗结果及治疗相关毒副作用。结果 20例婴儿ALL,中危7例,高危13例;诱导完全缓解(CR)率100%;治疗相关死亡(TRM)10%(2/20);2年累积复发率为(17±0.11)%,2年总体生存率(OS)为(72±0.13)%,2年无事件生存率(EFS)为(67±0.13)%。12例婴儿AML,中危10例,高危2例;CR率为100%;TRM为8%(1/12);2年累积复发率为(34±0.16)%,2年OS为(83±0.11)%,2年EFS为(61±0.16)%。结论CCLG-ALL 2008方案治疗婴儿ALL,CR率高,复发率低;BCH-AML 05方案治疗婴儿AML获得了与年长儿童相同的疗效。Objective To analyze the efficacy of CCLG-ALL 2008 and BCH-AML 05 regimens in the treatment of infant leukemia,so as to provide clinical data for improving the outcome of infant leukemia.Methods 32 infants with leukemia who met the criteria for admission from January 2011 to January 2019 were analyzed.Of the 32 patients,20 cases with acute lymphoblastic leukemia(ALL)received CCLG-ALL 2008 regimen,including 12 infants with MLL gene rearrangement(MLL-r)and 8 infants without MLL-r.The other 12 infants with acute myeloid leukemia(AML)were treated with BCHAML 05 regimen.A retrospective analysis was made concerning patients;prognosis,treatment-related toxicities and side effects.Results Among 20 infants with ALL,7 infants were at moderate risk and 13 were at high risk,and the complete remission(CR)rate of induction was 100%,treatment-related mortality(TRM)was 10%(2/20).The 2-year cumulative recurrence rate was(17 ±0.11)%.The 2-year overall survival(OS)and the 2-year event-free survival(EFS)of ALL infants were(72±0.13)%and(67±0.13)%,respectively.In addition,in the 12 infants with AML,10 were at moderate risk and 2 were at high risk.The CR of induction was 100%.The incidence of TRM was 8%(1/12).The 2-year cumulative recurrence rate was(34±0.16)%,2-year OS was(83±0.11)%,and the 2-year EFS was(61±0.16)%.Conclusions CCLG-ALL 2008 regimen has high CR rate and low recurrence rate for infant ALL.BCH-AML 05 regimen for infantile AML can achieve the same efficacy as that of older children.

关 键 词：婴儿白血病 CCLG-ALL 2008方案 BCH-AML 05方案 化疗 

分 类 号：R733.7[医药卫生—肿瘤]